Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy
/in Hepatocellular Carcinoma, International Publications, Newcastle Disease Virus /von 2016-04-27 / J. Pharmacol. Sci. 2016 Sep;132(1):24-30Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2016-04-21 / Radiat Oncol 2016 Apr;11:60Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy
/in International Publications, Newcastle Disease Virus /von 2016-04-20 / Oncolytic Virother 2016;5:27-34Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms
/in Hyperthermia, International Publications /von 2016-04-18 / Int J Hyperthermia 2016 06;32(4):446-54Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro
/in Exosome, Hepatocellular Carcinoma, International Publications /von 2016-04-15 / Hepatology 2016 08;64(2):456-72Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
/in Dendritic Cells, International Publications /von 2016-04-15 / Clin. Cancer Res. 2016 Apr;22(8):1897-906T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-04-11 / Cancer Res. 2016 06;76(12):3496-506Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer
/in Colorectal Cancer, Hyperthermia, International Publications /von 2016-03-30 / Radiat Oncol J 2016 Mar;34(1):34-44Effects of hyperthermia as a mitigation strategy in DNA damage-based cancer therapies
/in Hyperthermia, International Publications /von 2016-03-26 / Semin. Cancer Biol. 2016 06;37-38:96-105
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de